Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

he Company from Janssen under the collaboration and license agreement.Pharmacyclics, Inc.
Condensed Consolidated Statements of Operations(unaudited; in thousands, except per share data) Three Months EndedSix Months EndedDec. 31,Sep. 30,Dec. 31,Dec. 31, Dec. 31,20122012201120122011Revenue:  License and milestone revenue

$ 55,000$ 100,000$ 77,605$ 155,000$   77,605  Collaboration services revenue

2,9632,6952985,658335Total revenue

57,963102,69577,903160,65877,940Operating expenses*:  Research and Development

27,56719,07212,07646,63923,324  Less: Excess amounts related to Research and Development

(17,306)--(17,306)-Research and Development, net

10,26119,07212,07629,33323,324  General and Administrative

7,2254,8683,94412,0937,294  Less: Excess amounts related to General and Administrative

(819)--(819)-General and Administrative, net

6,4064,8683,94411,2747,294Total operating expenses

16,66723,94016,02040,60730,618Income from operations

41,29678,75561,883120,05147,322Interest and other income, net

77522112944Income before income taxes

41,37378,80761,904120,18047,366Income tax benefit (provision)

554(3,201)(5,651)(2,647)(5,651)Net income

$ 41,927$   75,606$ 56,253$ 117,533$   41,715Net income per share:Basic

$
.60$
.09$
.82$
.69$
.61Diluted

$
.56$
.02$
.78$
.58$
.58Weighted average shares used to computenet income per share:Basic

69,83969,51268,65869,67668,491Diluted

74,39974,45671,72574,40871,312* Includes share-based compensation as follows:Research and development

$   2,767$
2,590$   1,701$
5,357$
3,239General and administrative

1,5035766752,0791,301$   4,270$
3,166$   2,376$
7,436$
4,540Reconciliation of Selected GAAP Measures to Non-GAAP Measures (1) '/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market ... their offering. The global companion diagnostics ... 22.7% from 2014 to 2019. Factors such as rising ... of companion diagnostics by the pharmaceutical industry, support from ...
(Date:9/18/2014)... 18, 2014  U.S. biotech company Kultevat ... license for technology developed by the Donald Danforth ... plants, including for applications in production of natural rubber ... technology was developed under the direction of Roger ... former president of the Danforth Plant Science Center, and ...
(Date:9/18/2014)... 18, 2014  Neogen Corporation (Nasdaq: NEOG ... strategic agreement with Merck Animal Health to market Neogen,s ... The Igenity Dairy Heifer Program consists of genomic tests ... genetic potential of replacement dairy heifers. The genomic tests ... and is an excellent tool in the decision-making process ...
(Date:9/18/2014)... 18 septembre 2014 Mapi, société créée ... 1974, a été depuis 40 ans l,un ... cliniques traditionnelles par des évaluations recentrées sur ... les impacts économiques des traitements. ... A cours d,une récente conférence téléphonique ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2Merck Animal Health to market Neogen's dairy genomic program 21974 - 2014 - Mapi fĂȘte ses 40 ans 2
... Scimitar Equity, LLC issues a review ... entitled, "510k,Application Submitted for Xyfid(TM) and Priority ... Price Appreciation.", This review is available ... Pharmaceuticals is a New Jersey-based biotechnology company,dedicated ...
... 29 Zenobia Therapeutics, Inc.,(Zenobia) announced today ... award from The Michael J. Fox Foundation ... with potential to,fundamentally alter the course of ... Christopher Ross of Johns Hopkins University,Zenobia will ...
... July 29 ArunA Biomedical, Inc., the first,company ... and,services, announced today that William T. Sharp has ... to his ArunA leadership,responsibilities, Mr. Sharp has also ... succeeds ArunA founder Steven Stice, PhD, who will,remain ...
Cached Biology Technology:VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC 2Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2ArunA Biomedical Names William T. Sharp President and Chief Executive Officer 2
(Date:9/18/2014)... researchers from McGill University and the Quebec government ... ,microbeads, Canadian Journal of Fisheries and Aquatic ... cosmetics, household cleansers, or industrial cleansers, to which ... their small size and buoyancy, they may readily ... a global contaminant in the world,s oceans, but ...
(Date:9/18/2014)... creatively manipulate spoken language is unique to humans. "The ... years of human evolution to make this possible are ... we now have," says Wolfgang Enard, Professor of Anthropology ... understand the molecular biological basis of language Enard has ... his latest study, undertaken in collaboration with scientists at ...
(Date:9/18/2014)... and ethnic groups describe losing eyesight as potentially ... more so than other conditions including: loss of ... 49% of non-Hispanic whites, 43% of Asians and ... ailment is the worst that could happen to ... AIDS/HIV. Hispanics and Asians ranked cancer first ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... not the size of the eyespots on a male ... Instead, females are attracted to the "sparkle" created by ... at the center of eyespots, according to new research ... be published online June 29 in the Proceedings of ...
... between the two viruses could one day lead to ... researcher has discovered an unexpected link between the viruses ... an experimental strain of the human AIDS virus appear ... version of the disease as those immunized with the ...
... in a single gene can result in two ... to frequent or unusually severe infections, according to ... Nature Genetics. The discovery may lead to new ... A (IgA) deficiency and common variable immunodeficiency (CVID). ...
Cached Biology News:Female butterflies go for sparkle -- not size -- when choosing to mate 2Female butterflies go for sparkle -- not size -- when choosing to mate 3UF scientist finds unexpected link between cat and human AIDS viruses 2Agreement will speed research on microbicides for women 2Agreement will speed research on microbicides for women 3
Request Info...
R26.4C...
... x H): 17 3/4" x 8 ... slidesTime: Programmable 0 - 100 hoursControl: Programmable ... steps 40 user programmable protocols 3 operating ... Rapid temperature ramp-up from 37 - 95C ...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Biology Products: